Acorda Therapeutics, Inc. Q2 2010 Earnings Call Transcript

Acorda Therapeutics, Inc. (ACOR)

Q2 2010 Earnings Call

August 3, 2010 8:30 AM ET

Executives

Tierney Saccavino – SVP, Corporate Communications

Dr. Ron Cohen – President and CEO

David Lawrence – Chief Financial Officer

Analysts

Joel Sendek – Lazard Capital

Geoff Meacham – JPMorgan

Raghuram Selvaraju – Noble Financial Group

Yaron Werber – Citi

Phil Nadeau – Cowen and Company

David Amsellem – Piper Jaffray

Navin Jacob – ISI

Michael Yee – RBC

Josh Schwimmer – Leerink Swann

Presentation

Operator

Compare to:
Previous Statements by ACOR
» Acorda Therapeutics, Inc. Q1 2010 Earnings Call Transcript
» Acorda Therapeutics Inc. Q4 2008 Earnings Call Transcript
» Acorda Therapeutics, Inc., Q3 2008 Earnings Call Transcript

Welcome to Acorda Therapeutics Second Quarter 2010 Financial Results Conference Call. At this time, all participants are in listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company’s request.

I’d now like to introduce your host for today’s call, Ms. Tierney Saccavino, Senior Vice President of Corporate Communications at Acorda Therapeutics. Please go ahead, sir.

Tierney Saccavino

Thank you. Good morning, everyone, and welcome. With me today are Dr. Ron Cohen, our President and Chief Executive Officer; and David Lawrence, our Chief Financial Officer.

Before we begin, let me remind you that this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts regarding management’s expectations, beliefs, goals, plans, or prospects should be considered forward-looking.

These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics’ ability to successfully market and sell Ampyra in the United States and to successfully market Zanaflex Capsules, the risk of unfavorable results from future studies of Ampyra, the occurrence of adverse safety events with our product, delays in obtaining or failure to obtain regulatory approval of Ampyra outside the United States, and our dependence on our collaboration partner Biogen Idec in connection therewith, competition, failure to protect Acorda Therapeutics’ intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support of Acorda Therapeutics’ operations and unfavorable results from our preclinical programs.